← Human Trials & Peer-Reviewed Studies
Intranasal nicotine spray does not augment the adverse effects of cigarette smoking on myocardial oxygen demand or coronary arterial dimensions.
Plain-language guide to PMID 8873505 (1996): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 8873505
- Journal
- The American journal of medicine
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Keeley EC et al. (8 authors)
- DOI
- 10.1016/s0002-9343(96)00237-9
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
Nicotine replacement therapy has become a popular therapy for smokers attempting to stop smoking.
Unfortunately, some subjects continue to smoke while receiving it.
This study was performed to assess the effects of cigarette smoking with and without concomitant intranasal nicotine spray on: (a) myocardial oxygen demand, (b) coronary arterial dimensions, and (c) the development of acute cardiovascular tolerance.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
In 19 smokers referred for cardiac catheterization for the evaluation of chest pain, the researchers assessed the effects of cigarette smoking with and without concomitant intranasal nicotine spray on: (a) heart rate-systolic arterial pressure product (an estimate of myocardial oxygen demand), (b) coronary arterial dimensions (measured with computer-assisted quantitative arteriography), and (c) the development of acute cardiovascular tolerance.
How the Study Was Run
The design is described as randomized.
The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
What Was Measured
The subject headings attached to it are Cardiac Catheterization, Cineangiography, Coronary Angiography, Coronary Vessels, Heart Rate, Myocardium and Nicotine.
What This Means in Plain Language
The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 1996 (The American journal of medicine), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.